Collaboration supports the manufacture of the OPTF01 product to stimulate the development of T cells of the new generation chimerical antigen (CAR-T)
Indianapolis And Ehime, Japan,, May 5, 2025 / Prnewswire/-Genezen, a leading viral vector contract development and manufacturing organization (CDMO), and Optieum Biotechnologies, Inc. (Optieum), A Preclinical Stage Company DEDICATED to the Discovery and Development of Innovative CAR-T Cell Therapies, TODAY ANNOUNCED A Partnership for CGMP Manufacturing of the Lentiviral Vector (LVV) Construct used in the production of optf01, a novel therapy CAR-T for the treatment of glioblastoma.
Derived from the Embody system owner of Optieum, OPTF01 specifically targets the activation protein of fibroblasts (FAPα), a protein expressed on tumor cells and surrounding pericytes and fibroblasts associated with cancer (CAF). Therefore, the OPTF01 can potentially disturb the immunosuppressive microenvironment around the tumor while simultaneously attacking malignant cells in the tumor. The successful development of this therapeutic approach would meet a critical critical medical need for patients with refractory glioblastoma which are currently faced with limited treatment options with poor forecasts, as well as various other indications of solid tumors.
Under this collaboration, Gennezen will provide technology transfer, process development and CGMP manufacturing of LVV construction used in production to the production of the OPTF01 CAR-T product. “Gennezen is honored to support the best Optieum car-t programs with our best class LVV expertise to give life to these critical therapies,” said Steve FavaloroChairman and CEO of Genezen. “This collaboration with Optieum underlines our rich experience and the capacities of our people and our advanced facilities to support customers on a global scale – now including a leading Japanese biotechnology.”
Shun NishiokaCEO of Optieum added: “At Optieum, we are committed to redefining the future of CAR-T therapy thanks to incessant innovation and scientific rigor. The partnership with the team of experts from Genezen guarantees that critical materials for our revolutionary therapies are manufactured according to the highest standards, accelerating our progress.
OPTF01 is derived from the EUMBODY system, a owner platform representing a significant progression of the development of the therapy of CAR-T cells. This platform uses rapid and expansive functional screening to identify and optimize car constructions in an unprecedented manner. By dynamically harmonizing the sequences of variable single chain fragments (SCFV) to improve the functional capacities of T cells, the EUMBODY system establishes a new standard in CAR-T innovation.
Heal
Gennezen is a CDMO of gene therapy in the best category with more than a decade of experience and manufacturing facilities for advanced viral vectors. With work capacities through vector modality – from concept to advertising – GENEZEN helps innovative companies to provide vital genetic and cellular therapies worldwide. With flexible and client -focused programs, Gennezen adapts his partnership model approach for all sizes and stages of organizations, university establishments and companies funded by seeds to large multinational biopharmatic companies. For more information, please visit www.genezen.com And follow us Liendin.
About optical biotechnologies
OPTIEUM Biotechnologies Inc. is a cutting-edge biotechnology company dedicated to the hope of engineering for patients thanks to the development of cellular therapies of CAR-T nexter. At the heart of Optieum innovation is its owner Embody system, a revolutionary platform that optimizes car constructions to unlock the complete therapeutic potential of T cells by dynamically harmonizing the car liaison areas. This transformative platform has the potential to redefine the therapy of CAR-T cells, allowing the development of revolutionary treatments for difficult diseases. For more information, visit http://www.optieumbio.com And follow us Liendin.
Logo – https://mma.prnewswire.com/media/2679070/genezen_logo_rgb_logo.jpg
Logo – https://mma.prnewswire.com/media/2679071/optieum_logo.jpg
Show the original content:https://www.prnewswire.com/apac/news-releases/genezen-and-optieum-biotechnologies-partner-putport-cgmp-mahufacturing-of-groundbriaking-car-therapy-for-glioblastoma-30245962.html
Healed source
